---
title: 'MOMENT registry: Patients with advanced non-small-cell lung cancer harboring
  <em>MET</em> exon 14 skipping treated with systemic therapy'
date: '2025-01-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39836056/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250121170941&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Aim: MET exon 14 (METex14) skipping occurs in 3-4% of non-small-cell
  lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label,
  single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing
  was only recently introduced in many countries, there is a lack of historical real-world
  data from patients with METex14 skipping NSCLC receiving conventional therapies.
  Given the rarity of this population and limitations of existing real-world data
  sources, ...'
disable_comments: true
---
Aim: MET exon 14 (METex14) skipping occurs in 3-4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical real-world data from patients with METex14 skipping NSCLC receiving conventional therapies. Given the rarity of this population and limitations of existing real-world data sources, ...